Apr 09, 2020
IFFGD's IBS Patients' Illness Experience and Unmet Needs Survey
Mar 09, 2020
The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026
Mar 09, 2020
Canadians suffering from diarrhea-predominant Irritable Bowel Syndrome (IBS-D) have a new clinically proven option approved by Health Canada
Feb 17, 2020
Irritable Bowel Syndrome Treatment Market to Reach $2.01 Bn, Globally, by 2026 at 8.2% CAGR, Says Allied Market Research
Feb 12, 2020
Immuron reports diarrhea no.1 health issue for Americans on vacation
Feb 11, 2020
InventHelp Inventor Develops Personal Hygiene Accessory for the Anus (LAX-1098)
Jan 27, 2020
Irritable Bowel Syndrome (IBS) Product Earns Top Spot from TopConsumerReviews.com
Oct 30, 2019
Study Shows Human Milk Oligosaccharides Significantly Improve IBS Symptoms
Aug 07, 2019
In the Longest-Ever String of Yearly Surveys on Gastroenterologists' Preferences for Recommending Products for IBS, IBgard Continues to Widen its Already Pre-Eminent "#1 Recommended"(1) Status
Aug 07, 2019
First-Ever 36 Month Real-World, Post-Marketing Surveillance Study Confirms The Excellent Safety And Tolerability Profile Of IBgard®, A Non-Prescription Product For IBS
May 14, 2019
Salix Pharmaceuticals Marks 30-Year Anniversary With Largest Showing Of Data At Digestive Disease Week
Apr 25, 2019
Global $385 Mn Traveler's Diarrhea Markets, 2019-2028
Apr 04, 2019
Enteromed Conducts New Clinical Research into Irritable Bowel Syndrome that can Offer Real Hope and Drug Free Relief to Patients
Apr 01, 2019
FDA approves the reintroduction of Zelnorm(TM) (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65
Mar 28, 2019
IFFGD Encourages Patients to Share "What I Wish People Understood About My IBS" for IBS Awareness Month
Mar 27, 2019
Traveler's Diarrhea Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Dec 11, 2018
Atrantil Is Now For Sale Direct To Consumers In Canada
Dec 06, 2018
ZAXINE® (rifaximin) - Now Indicated in Canada for Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)1,2
Nov 19, 2018
FDA Approves AEMCOLO(TM) (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade
Nov 16, 2018
FDA approves new drug to treat travelers' diarrhea